Biotech Giants Clash Over mRNA Vaccine Patents
German biotech firm CureVac has filed a lawsuit against Moderna in Delaware, alleging patent infringement of its mRNA technology in Moderna's COVID-19 vaccine, Spikevax. The case is among several patent disputes in the biotech sector as companies vie for royalties from successful COVID-19 vaccines.
CureVac, a German biotech company, has initiated legal proceedings against Moderna in Delaware federal court, asserting that Moderna's COVID-19 vaccine, Spikevax, infringes on CureVac's patents concerning messenger RNA (mRNA) technology.
The lawsuit claims Moderna improperly utilized CureVac's stabilization technology for fragile mRNA in its vaccines and seeks royalties from Spikevax sales. CureVac's move follows BioNTech's acquisition and subsequent separate patent lawsuit against Moderna earlier this year.
This legal action is part of a broader wave of high-stakes patent litigation in the biotech industry as companies aim for compensation for technologies used in lucrative COVID-19 vaccines. The ongoing legal battles include a suit Moderna filed against Pfizer and BioNTech in 2022.
ALSO READ
-
Erica Schwartz's Controversial CDC Nomination Amid Vaccine Policy Disputes
-
Erica Schwartz's CDC Nomination Shifts Focus Away from Controversial Vaccine Policies
-
Uncertain Times for COVID-19 Vaccines as New Season Approaches
-
Erica Schwartz's CDC Nomination: A New Direction Amid Vaccine Policy Turmoil
-
Robert F. Kennedy Jr. Advocates for Independence in CDC Vaccine Decisions
Google News